SE507682C2 - Farmaceutisk beredning för behandling av gastrit, refluxesofagit, duodenit, dyspepsi och magsårssjukdom innehållande en blandning av ammoniumvismutcitrat och ett alginat - Google Patents

Farmaceutisk beredning för behandling av gastrit, refluxesofagit, duodenit, dyspepsi och magsårssjukdom innehållande en blandning av ammoniumvismutcitrat och ett alginat

Info

Publication number
SE507682C2
SE507682C2 SE9601219A SE9601219A SE507682C2 SE 507682 C2 SE507682 C2 SE 507682C2 SE 9601219 A SE9601219 A SE 9601219A SE 9601219 A SE9601219 A SE 9601219A SE 507682 C2 SE507682 C2 SE 507682C2
Authority
SE
Sweden
Prior art keywords
alginate
patients
bismuth
treatment
biogastrin
Prior art date
Application number
SE9601219A
Other languages
English (en)
Swedish (sv)
Other versions
SE9601219L (sv
SE9601219D0 (sv
Inventor
Marcin Krotkiewski
Original Assignee
Marcin Krotkiewski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marcin Krotkiewski filed Critical Marcin Krotkiewski
Priority to SE9601219A priority Critical patent/SE507682C2/sv
Publication of SE9601219D0 publication Critical patent/SE9601219D0/xx
Priority to JP9535200A priority patent/JP2000507572A/ja
Priority to PCT/SE1997/000544 priority patent/WO1997036599A1/en
Priority to RU98119709/14A priority patent/RU2193407C2/ru
Priority to EP97916696A priority patent/EP0910388B1/en
Priority to AU25253/97A priority patent/AU2525397A/en
Priority to ES97916696T priority patent/ES2184081T3/es
Priority to PL97329152A priority patent/PL329152A1/xx
Priority to DE69715625T priority patent/DE69715625T2/de
Priority to AT97916696T priority patent/ATE224197T1/de
Publication of SE9601219L publication Critical patent/SE9601219L/xx
Publication of SE507682C2 publication Critical patent/SE507682C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9601219A 1996-03-29 1996-03-29 Farmaceutisk beredning för behandling av gastrit, refluxesofagit, duodenit, dyspepsi och magsårssjukdom innehållande en blandning av ammoniumvismutcitrat och ett alginat SE507682C2 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9601219A SE507682C2 (sv) 1996-03-29 1996-03-29 Farmaceutisk beredning för behandling av gastrit, refluxesofagit, duodenit, dyspepsi och magsårssjukdom innehållande en blandning av ammoniumvismutcitrat och ett alginat
AT97916696T ATE224197T1 (de) 1996-03-29 1997-03-27 Arzneipräparat zur behandlung der gastritis, der reflux-ösophagitis, duodenitis,dyspepsie und ulkuserkrankungen
EP97916696A EP0910388B1 (en) 1996-03-29 1997-03-27 Pharmaceutical preparation for the treatment of gastritis, reflux oesophagitis, duodenitis, dyspepsia and ulcer disease
PCT/SE1997/000544 WO1997036599A1 (en) 1996-03-29 1997-03-27 Pharmaceutical preparation for the treatment of gastritis, reflux oesophagitis, duodenitis, dyspepsia and ulcer disease
RU98119709/14A RU2193407C2 (ru) 1996-03-29 1997-03-27 Фармацевтические препараты для лечения гастритов, рефлюкс-эзофагитов, дуоденитов, диспепсии и язвы
JP9535200A JP2000507572A (ja) 1996-03-29 1997-03-27 胃炎、逆流食道炎、十二指腸炎、消化不良および潰瘍の治療用調合薬品
AU25253/97A AU2525397A (en) 1996-03-29 1997-03-27 Pharmaceutical preparation for the treatment of gastritis, reflux oesophagitis, duodenitis, dyspepsia and ulcer disease
ES97916696T ES2184081T3 (es) 1996-03-29 1997-03-27 Preparacion farmaceutica para el tratamiento de la gastritis, de la esofagitis por reflujo, de la duodenitis, de la dispepsia y de la ulcera.
PL97329152A PL329152A1 (en) 1996-03-29 1997-03-27 Pharmaceutic preparation for treating gastritis, refluxive oesophagitis, duodenitis, indigestion and chronic peptic ulcer disease
DE69715625T DE69715625T2 (de) 1996-03-29 1997-03-27 Arzneipräparat zur behandlung der gastritis, der reflux-ösophagitis, duodenitis,dyspepsie und ulkuserkrankungen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9601219A SE507682C2 (sv) 1996-03-29 1996-03-29 Farmaceutisk beredning för behandling av gastrit, refluxesofagit, duodenit, dyspepsi och magsårssjukdom innehållande en blandning av ammoniumvismutcitrat och ett alginat

Publications (3)

Publication Number Publication Date
SE9601219D0 SE9601219D0 (sv) 1996-03-29
SE9601219L SE9601219L (sv) 1997-09-30
SE507682C2 true SE507682C2 (sv) 1998-07-06

Family

ID=20402012

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9601219A SE507682C2 (sv) 1996-03-29 1996-03-29 Farmaceutisk beredning för behandling av gastrit, refluxesofagit, duodenit, dyspepsi och magsårssjukdom innehållande en blandning av ammoniumvismutcitrat och ett alginat

Country Status (10)

Country Link
EP (1) EP0910388B1 (xx)
JP (1) JP2000507572A (xx)
AT (1) ATE224197T1 (xx)
AU (1) AU2525397A (xx)
DE (1) DE69715625T2 (xx)
ES (1) ES2184081T3 (xx)
PL (1) PL329152A1 (xx)
RU (1) RU2193407C2 (xx)
SE (1) SE507682C2 (xx)
WO (1) WO1997036599A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9621273D0 (en) 1996-10-11 1996-11-27 Cortecs Ltd Therapeutic method
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
GB0012487D0 (en) 2000-05-24 2000-07-12 Pfylori Limited Use of metal compounds to treat gastrointestinal infections
AU2002356493A1 (en) * 2001-11-19 2003-06-10 Nobel Ilac Sanayii Ve Ticaret A.S. New pharmaceutical combinations prepared with alginates and biphosphonates in order to prevent gastroesophageal reflux during use of oral biphoshonates
AU2005237246A1 (en) * 2004-04-30 2005-11-10 Nycomed Gmbh Method of classifying GERD
JP2006342085A (ja) * 2005-06-08 2006-12-21 Kao Corp Ｇｉｐ分泌抑制剤
CN102558383B (zh) * 2012-01-10 2014-07-23 中国科学院海洋研究所 一种海藻酸铋及其制备方法和应用
CN104524356A (zh) * 2014-12-11 2015-04-22 吴燕 一种治疗返流性食道炎的中药组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
AU609999B2 (en) * 1988-06-21 1991-05-09 Marion Laboratories, Inc. Bismuth (phosph/sulf)ated saccharides
GB2272375B (en) * 1992-04-10 1996-02-14 Vnii Med Polimerov Pharmaceutical composition
WO1995025521A1 (en) * 1994-03-24 1995-09-28 The Procter & Gamble Company Solid dose forms containing bismuth

Also Published As

Publication number Publication date
EP0910388A1 (en) 1999-04-28
ATE224197T1 (de) 2002-10-15
PL329152A1 (en) 1999-03-15
ES2184081T3 (es) 2003-04-01
SE9601219L (sv) 1997-09-30
AU2525397A (en) 1997-10-22
EP0910388B1 (en) 2002-09-18
SE9601219D0 (sv) 1996-03-29
RU2193407C2 (ru) 2002-11-27
WO1997036599A1 (en) 1997-10-09
DE69715625T2 (de) 2003-06-12
JP2000507572A (ja) 2000-06-20
DE69715625D1 (de) 2002-10-24

Similar Documents

Publication Publication Date Title
Logan et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole.
El-Omar et al. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine.
McCarthy Sucralfate
Labenz et al. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study.
JP5908569B2 (ja) 胃腸疾患を治療するための方法
Davenport et al. Prevalence of Helicobacter pylori in patients with end-stage renal failure and renal transplant recipients
Nakajima et al. Helicobacter pylori in patients receiving long-term dialysis
JPS6248623A (ja) 胃腸疾患の治療のための医薬組成物
JPH0794391B2 (ja) 胃腸疾患の治療用医薬組成物
KR102351422B1 (ko) 철 트리말톨의 복용량 양생법
Ramteke et al. Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori
PT2415475E (pt) Composição farmacêutica compreendendo um inibidor da bomba de protões e um prebiótico para o tratamento de lesões ulcerosas do estômago e duodeno
Borody et al. Helicobacter pylori Eradication with Doxycycline—Metronidazole—Bismuth Subcitrate Triple Therapy
Bago et al. Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial
SE507682C2 (sv) Farmaceutisk beredning för behandling av gastrit, refluxesofagit, duodenit, dyspepsi och magsårssjukdom innehållande en blandning av ammoniumvismutcitrat och ett alginat
van Zanten et al. Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection
Seyyedmajidi et al. Correlation between creatinine clearance and Helicobacter pylori infection eradication with sequential and triple therapeutic regimens: a randomised clinical trial
KR101277028B1 (ko) 인 장해 예방 개선 치료제, 음식품 또는 약품 중 인산 이온을 흡착하기 위한 경구제 및 이들의 제조 방법
Krakowka et al. Antimicrobial therapies for Helicobacter pylori infection in gnotobiotic piglets
Berstad et al. Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway
Sattler et al. Safety of aztreonam and SQ 26,992 in elderly patients with renal insufficiency
Tan et al. pH-responsive polymeric micelle dynamic complexes for selective killing of Helicobacter pylori
Adachi et al. Comparative study of the speed of acid‐suppressing effects of oral administration of cimetidine and famotidine
US20030180381A1 (en) Use of metal compounds to treat gastrointestinal infections
Qureshi et al. Diagnosis and management of Helicobacter pylori infection

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 9601219-0

Format of ref document f/p: F